16 februari 2018: Brons ASCO GU 2018

Wanneer darmkankerpatiënten met hoog risico op een recidief (stadium III) na een operatie een 6 maanden chemokuur krijgen met CAPOX = Capecitabine - Xeloda plus oxaliplatin dan hebben zij 10 procent meer kans om op 3 jaar nog steeds ziektevrij te zijn dan wanneer zij FOLFOX = 5-FU + Leucovarin + oxaliplatin krijgen als chemokuur. In mediane overall overleving zit weinig verschil tussen beide chemokuren. CAPOX geeft wel andere en ernstiger bijwerkingen dan FOLFOX en bij meer patiënten moest de dosering worden aangepast, zo blijkt uit een fase III studie en gepresenteerd op ASCO GU 2018.

Belangrijke conclusie: 

Als de chemokuren slechts drie maanden gegeven zouden worden i.p.v. 6 maanden dan zou 28.7% van de patiënten die FOLFOX kregen en 20.5% die CAPOX kregen nooit een recidief hebben gekregen (P=0.0008). Dus de ziektevrije tijd op 3 jaar was voor CAPOX beter bij 6 maanden chemo maar als de chemo slechts drie maanden gegeven zou worden zou de kans op een recidief op langere termijn voor FOLFOX minder zijn dan voor CAPOX.

Ik ga niet alles vertalen en zie ook in gerelateerde artikelen andere vormen van chemotherapie en lees ook onze literatuurlijsten niet-toxische stoffen bij darmkanker of chemo.

Hier de TAKE home message van de studie (abstract staat onderaan dit artikel plus referentielijst:

Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer

TAKE-HOME MESSAGE

Het abstract:

CAPOX may be associated with improved DFS despite greater toxicities and lower RDI. Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT.

Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer

Jonathan M. Loree
,
Aaron Sha
,
Maryam Soleimani
,
Hagen F. Kennecke
,
Maria Y. Ho
,
Winson Y. Cheung
,
Karen E. Mulder
,
Shirin Abadi
,
Jennifer L. Spratlin
,
Sharlene Gill'Correspondence information about the author Sharlene Gill

Abstract (<250 words)

Background

CAPOX and FOLFOX are both used in the adjuvant treatment of colon cancer, and while their efficacy is assumed to be similar, they have not been directly compared. We reviewed the toxicity profiles, relative dose intensity (RDI) and survivals associated with these regimens across a multi-institutional cohort.

Methods

We identified 394 consecutively treated patients with stage III colon cancer who received an oxaliplatin containing regimen. RDI was defined as the total dose received divided by the intended total dose if all cycles were received.

Results

FOLFOX was associated with increased mucositis (6.2% vs 0.7%, P=0.0069) and neutropenia (25.9% vs 8.6%, P<0.0001), while CAPOX was associated with increased dose limiting toxicities (DLTs) (90.7% vs 80.2%, P=0.0055), diarrhea (31.8% vs 9.0%, P<0.0001) and hand-foot syndrome (19.9% vs 2.1%, P<0.0001). Higher median RDI of fluoropyrimidine (93.7% vs 80.0%, P<0.0001) and oxaliplatin (87.2% vs 76.3%, P<0.0001) was noted for patients receiving FOLFOX. Reducing the duration from 6 to 3 months would have prevented 28.7% of FOLFOX and 20.5% of CAPOX patients from ever experiencing a DLT (P=0.0008). Overall survival did not differ by regimen (HR 0.73, 95%CI 0.45-1.22; P=0.24), however CAPOX was associated with an improved disease-free survival (DFS) (3-year DFS 83.8% vs 73.4%, P=0.022), which remained significant in high risk (T4 or N2) (P=0.039) but not low risk patients (P=0.19).

Conclusions

CAPOX may be associated with improved DFS despite greater toxicities and lower RDI. Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT.

References

  1. Böckelman, C., Engelmann, B.E., Kaprio, T., Hansen, T.F., Glimelius, B. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol (Madr). 2015;54:5–16 .
  2. Loree, J.M., Cheung, W.Y. Optimizing adjuvant therapy and survivorship care of stage III colon cancer. Futur Oncol. 2016;12:2021–2035 .
  3. Moertel, C.G., Fleming, T.R., Macdonald, J.S. et al, Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma. N Engl J Med. 1990;322:352–358 .
  4. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23(34):8671–8678. doi:10.1200/JCO.2004.00.5686..
  5. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–944. http://www.ncbi.nlm.nih.gov/pubmed/7715291. Accessed January 11, 2016..
  6. André T, De Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33. doi:10.1200/JCO.2015.63.4238..
  7. Maniadakis, N., Fragoulakis, V., Pectasides, D., Fountzilas, G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin. 2009;25:797–805 .
  8. Di Costanzo, F., Ravasio, R., Sobrero, A. et al, Capecitabine versus Bolus Fluorouracil plus Leucovorin ( Folinic Acid ) as Adjuvant Chemotherapy for Patients with Dukes ’ C Colon Cancer Economic Evaluation in an Italian NHS Setting. Clin Drug Investig. 2008;28:645–655.
  9. Best, J., Garrison, L. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10:103–114.
  10. Ho, M.Y., Chang, A.Y., Ruan, J.Y., Cheung, W.Y. Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer. Clin Colorectal Cancer. 2016;15:158–163 .
  11. Twelves, C., Scheithauer, W., Mckendrick, J. et al, Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190–1197 .
  12. Schmoll, H.J., Twelves, C., Sun, W. et al, Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: A pooled analysis of individual patient data from four randomised controll. Lancet Oncol. 2014;15:1481–1492 .
  13. Schmoll H-J, Tabernero J, Maroun J, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015;33(32):3733–3740. doi:10.1200/JCO.2015.60.9107..
  14. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–2012. doi:10.1200/JCO.2007.14.9898..
  15. Pectasides, D., Karavasilis, V., Papaxoinis, G. et al, Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 2015;15:384 .
  16. Loree, J.M., Mulder, K.E., Ghosh, S., Spratlin, J.L. Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer. J Gastrointest Cancer. 2014;45:154–160 .
  17. Loree, J.M., Mulder, K.E., Ghosh, S., Spratlin, J.L. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer. 2014;13:172–177 .
  18. Mamo, A., Easaw, J., Ibnshamsah, F. et al, Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting. Curr Oncol. 2016;23:171 .
  19. Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemother. J Clin Oncol. 2017;35(15_suppl):LBA1–LBA1. doi:10.1200/JCO.2017.35.15_suppl.LBA1..
  20. Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. Springer; 2010..
  21. Google. The Google Distance Matrix API | Google Maps Distance Matrix API | Google Developers. https://developers.google.com/maps/documentation/distancematrix/intro. Published 2015. Accessed August 18, 2015..
  22. de Gramont, A., Van Cutsem, E., Schmoll, H.-J. et al, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233 .
  23. Saif, M.W., Hashmi, S., Zelterman, D., Almhanna, K., Kim, R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008;23:139–145 .
  24. Kerbel, R.S., Shaked, Y. The potential clinical promise of “multimodality” metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett. 2017;400:293–304 .
  25. Bocci, G., Kerbel, R.S. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:659–673 .
  26. Biagi, J.J., Raphael, M.J., Mackillop, W.J., Kong, W., King, W.D., Booth, C.M. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305:2335–2342 .
  27. Andre T, Boni C, Navarro M, et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. 2009;27(19):3109–3116. doi:10.1200/JCO.2008.20.6771..
  28. Winterhalder R, Hoesli P, Delmore G, et al. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology. 2011;80(1-2):29–33. doi:10.1159/000328317..
  29. Bhattacharya, D., Easthall, C., Willoughby, K.A., Small, M., Watson, S. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract. 2012;18:333–342 .

Disclosures: None

Grant Support: JL is a member of the UBC Clinician Investigator program and was the recipient of the CAMO 2016 Research Fellowship, the J. Edward Mahoney Foundation ASCO YIA, and the RCPSC Detweiler Fellowship.


Plaats een reactie ...

Reageer op "CAPOX = Xeloda - capecitabine plus oxaliplatin geeft op 3 jaars meting 10 procent betere ziektevrije tijd (83 vs 73 procent) dan FOLFOX = 5-FU + Leucovarin + oxaliplatin bij darmkanker stadium III"


Gerelateerde artikelen
 

Gerelateerde artikelen

mFOLFOX6 - fluorouracil, leucovorin >> Stoppen met oxaliplatin geeft >> CAPOX = Xeloda - capecitabine >> S-1 plus irinotecan plus bevacizumab >> RFA naast systemische chemo >> Darmkankerpatienten jonger >> Oxaliplatin plus Xeloda - >> FOLFOXIRI + Bevacizumab geeft >> Oxaliplatin voegt niets toe >> Chemo bij endeldarmkanker >>